Mark Schneyer sold $69K of Acadia Pharmaceuticals stock
By AlphaYouPublished Form 4
Schneyer Mark C.
Reporting filer
Mark Schneyer reported selling 3,321 shares of Acadia Pharmaceuticals Inc for about $69K ($20.88 a share on average). Form 4 filed Oct 31, 2026 lists 2 entries.
See the price move since this trade →
- Disclosed
- Oct 31, 2026
Reported details
2 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Schneyer Mark C. | 2026-10-15 | A | Grant or award | 6815 | 0 | 74,643 | 16 days | Filed terms
|
| Common Stock | Schneyer Mark C. | 2026-10-30 | S | Sale | 3321 | 20.88 | 71,322 | 1 day | Filed terms
|
Common Stock
- Owner
- Schneyer Mark C.
- Date
- 2026-10-15
- Code
- A
- Action
- Grant or award
- Quantity
- 6815
- Price
- 0
- Following holdings
- 74,643
- Reporting delay
- 16 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-15
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Shares: 6815
- transaction Price Per Share: 0
- id: F1
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 74643
- direct Or Indirect Ownership: D
- nature Of Ownership:
Common Stock
- Owner
- Schneyer Mark C.
- Date
- 2026-10-30
- Code
- S
- Action
- Sale
- Quantity
- 3321
- Price
- 20.88
- Following holdings
- 71,322
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-30
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: 0
- id: F2
- transaction Shares: 3321
- transaction Price Per Share: 20.88
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 71322
- direct Or Indirect Ownership: D
- nature Of Ownership:
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Schneyer Mark C.: EVP, CHIEF FINANCIAL OFFICER.
- The filing reports a Rule 10b5-1 trading plan.
- F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024 and September 12, 2025, the performance stock units have vested at 100% of target.
- F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Original sources
Prepared automatically from public filing data. Report a correction.